Therapy and Monitoring

Screening and improved adjuvant treatments have increased breast cancer survival rates since the mid-1970s, with current 5 year survival rates at nearly Screening and improved adjuvant treatments have increased breast cancer survival rates since the mid-1970s, with current 5 year survival rates at nearly 90% in developing countries where there is access to screening and diagnosis.8 MRI, CESM, Mammography, PET/CT have been shown to be effective modalities in therapy monitoring.9,10, 11
8. Effect of screening and adjuvant therapy on mortality from breast cancer. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M. et al. N Engl J Med. 2005;353:1784–92.doi:10.1056/NEJMoa050518.
9. Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Iotti V1, Ravaioli S2, Vacondio R2, Coriani C2, Caffarri S3, Sghedoni R4, Nitrosi A4, Ragazzi M5, Gasparini E6, Masini C7, Bisagni G7, Falco G8, Ferrari G8, Braglia L9, Del Prato A2, Malavolti I3, Ginocchi V3, Pattacini P2. Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.
10. Mammography,Imaging Neoadjuvant Therapy.Response in Breast Cancer. Amy M. Fowler, MD, PhDDavid A. Mankoff, MD, PhD,Bonnie N. Joe, MD, PhD. radiology.rsna.org n Radiology: Volume 285: Number 2—November 2017
11. 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. Stefanie Avril, Raymond F. Muzic Jr., Donna Plecha, Bryan J. Traughber, Shaveta Vinayak, and Norbert Avril. Nucl Med. 2016 February ; 57(Suppl 1): 34S–39S. doi:10.2967/jnumed.115.157875.